AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01017302
Drug: RO5095932
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating subcutaneous doses once weekly over a 4 weeks period
Trial: NCT01017302
Drug: RO5095932
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutenaous dose in week 5
Trial: NCT00224640
Drug: Iron chelating intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron chelating intervention
Trial: NCT02015910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimick Sitagliptin 100mg pill.
Trial: NCT00699114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose as powder in gelatine capsules, single dose
Trial: NCT00699114
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400 mg as powder in gelatine capsules, single dose
Trial: NCT00699114
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 600 mg as powder in gelatine capsules, single dose
Trial: NCT00699114
Drug: Ibuprofen 800 mg
RxNorm normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 800 mg as powder in gelatine capsules, single dose
Trial: NCT00699114
Drug: Paracetamol (acetaminophen) 1000 mg + codeine 60 mg
RxNorm normalized name: codeine and paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose
Trial: NCT02490865
Drug: RNS60
RxNorm normalized name: Ronasin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNS60, 4 ml dose nebulized twice daily
Trial: NCT02490865
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline, 4 ml dose nebulized twice daily
Trial: NCT00648765
Drug: Agrylin® Capsules 1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg, single dose fed
Trial: NCT02785523
Drug: Ganoderma Spore Lipids
RxNorm normalized name: Ganoderma lucidum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02785523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02785523
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00654550
Drug: Nexagon™ or Nexagon™ vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalation design in which cohorts of 6 subjects will be studied sequentially.
Trial: NCT02503137
Drug: Topical SM04554 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02094157
Drug: Bridged regimen Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention is assigned to the active control arm - Bridged regimen
Trial: NCT00933543
Drug: Visonac PDT (MAL PDT)
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream application followed by illumination with red light.
Trial: NCT04257929
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT03427320
Drug: [131]I-IAZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of a single dose of 185MBq ( range 150-220MBq) of \[131\]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
Trial: NCT01744106
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01209689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02506348
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02506348
Drug: Nepafenac
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02353273
Drug: WH-1 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be applied the one dose of WH-1 ointment on Day 1, and twice a day of WH-1 application from Day 2 to Day 13, then one dose for Day 14.
Trial: NCT04190966
Drug: Integrated Pharmacotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated smoking cessation pharmacotherapy including choice of combination nicotine replacement therapy, varenicline or electronic cigarettes
Trial: NCT04179669
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT02644499
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic dise
Trial: NCT02644499
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop)
Trial: NCT02644499
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
Trial: NCT01054885
Drug: FF/GW642444 Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
Trial: NCT01054885
Drug: GW642444 Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long Acting Beta Agonist(LABA)
Trial: NCT01054885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00479427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT00807001
Drug: IDX184
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dose, active or placebo
Trial: NCT04004195
Drug: BAY2327949
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)
Trial: NCT02417506
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06343480
Drug: Labour Induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the use of misoprostol sublingual for labour induction compared with oxytocin titration in parturients with prelabour membrane rupture at term.
Trial: NCT01429740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution or capsules
Trial: NCT04057573
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Trial: NCT00696631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00712439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00068692
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00068692
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03570710
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
Trial: NCT04683614
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mic/kg/hr norepinephrine
Trial: NCT02583594
Drug: Ceterizine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablet Route of administration: oral
Trial: NCT04510818
Drug: Capecitabine, Camrelizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a single-arm study with all patients receiving these two drugs.
Trial: NCT02850913
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * 115 participants will be randomized to either oral Doxycycline 100 mg daily for six weeks.~* Treatment will be initiated in hospital but will be continued at home.~* Scheduled study clinic visits will be made by the participants at 6, 12 and 24 months.~* Each participant will be visited at home at 2, 4 and 6 weeks for adherence monitoring and assessment of safety
Trial: NCT00331097
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 intravenously days 1, 8 every 28 days
Trial: NCT00331097
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg/m2 intravenously days 1 and 8 every 28 days
Trial: NCT02298010
Drug: Capecitabine, oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00914316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily
Trial: NCT00543413
Drug: MK8141
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period
Trial: NCT00543413
Drug: Comparator: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK8141 Pbo tablet once daily. 4 week treatment period.
Trial: NCT03349034
Drug: Ropivicaine
RxNorm normalized name: Ropivicaine-Sufentanil Citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.2% Ropivacaine via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.
Trial: NCT03349034
Drug: Local Saline Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.9% normal saline via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.
Trial: NCT01737437
Drug: group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
Trial: NCT01737437
Drug: group LV
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Lidocaine was applied on laryngoscope blade and trachea.
Trial: NCT03848832
Drug: GWP42003-P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GWP42003-P presented as an oral solution containing cannabidiol
Trial: NCT03848832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral solution
Trial: NCT03723772
Drug: IGlar U100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.
Trial: NCT03279120
Drug: TFV/LNG IVR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used for 90 days (Continuous or Interrupted)
Trial: NCT03279120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used for 90 days (Continuous or Interrupted)
Trial: NCT03142282
Drug: maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: National Comprehensive Cancer Network (NCCN) or European Society for Medical Oncology (ESMO) suggested maintenance chemotherapy regimens: xeloda, bevacizumab
Trial: NCT00138723
Drug: SPM 907
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00145106
Drug: Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01757795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be intravenously administered
Trial: NCT02777866
Drug: Placebo: Infiltration of 0.9% Saline Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound
Trial: NCT02549391
Drug: KHK7580
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT02549391
Drug: KRN1493
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT03329638
Drug: Placebo Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Ophthalmic Solution dosed once daily for 12 months
Trial: NCT00565292
Drug: MK0859
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00602472
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to linagliptin 5 mg
Trial: NCT01189409
Drug: PEG then Senna
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped bowel protocol with PEG for 3 weeks followed by senna for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
Trial: NCT01189409
Drug: Senna then PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped bowel protocol with senna for 3 weeks followed by PEG for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
Trial: NCT04446104
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc tablet 80 mg/vitamin C 500mg daily for 42 days
Trial: NCT00475956
Drug: AZD2171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet multiple ascending doses 20, 30 or 45 mg
Trial: NCT00475956
Drug: AZD0530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet multiple ascending doses 125 mg or 175 mg
Trial: NCT00751608
Drug: APL180
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00751608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01908803
Drug: AL-60371/AL-817 otic suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01715740
Drug: Chinese Herbal Medicine (CHM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each CHM capsule, weighing 500mg, consists of XFS 250 mg and QSFFT 250 mg.
Trial: NCT01715740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated powder with similar taste, color, odor to intervention Chinese herbal medicine
Trial: NCT02004041
Drug: VLY-686
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02004041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01291732
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of matching placebo
Trial: NCT03335670
Drug: [68Ga]Pentixafor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga Pentixafor is a radiolabeled cyclic pentapeptide with high affinity for CXCR4 receptor
Trial: NCT04631250
Drug: 5-Aminolevulinic Acid-Containing Product in Cutaneous Dose Form
RxNorm normalized name: 5-aminolevulinic acid-containing product in cutaneous dose form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Aminolevulinic Acid was applied to both sides of the face.
Trial: NCT00910416
Drug: propofol, remifentanil, atracurium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol, remifentanil, atracurium dosages are adapted according to clinician's judgment
Trial: NCT00910416
Drug: propofol, remifentanil, atracurium, sevoflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosages are adapted according to clinician's judgment
Trial: NCT00885170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to odanacatib 50 mg tablets once weekly for 24 months
Trial: NCT02303327
Drug: Androgen deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)
Trial: NCT02282098
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Colchicine
Trial: NCT01371357
Drug: TEST 1
RxNorm normalized name: Bar Test 10% Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g/day of guanidinoacetic acid
Trial: NCT01371357
Drug: TEST 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
Trial: NCT01371357
Drug: TEST 4
RxNorm normalized name: urine phenaphthazine-pH test 4 X 15 feet MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
Trial: NCT01230983
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01230983
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01230983
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01230983
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01230983
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT03674853
Drug: Wuling Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take Wuling Capsule in experiment group for 2 months
Trial: NCT03674853
Drug: Oryzanol
RxNorm normalized name: Oryzanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take oryzanol in active comparator group for 2 months
Trial: NCT02900378
Drug: LCZ696 (Sacubitril/Valsartan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 (sacubitril/valsartan) was available in 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
Trial: NCT02900378
Drug: Placebo of LCZ696 (Sacubitril/Valsartan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of LCZ696 (sacubitril/valsartan) was available to match 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
Trial: NCT02070718
Drug: Standard Dose Kappa Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04686669
Drug: FOR-6219 capsule formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOR-6219 capsule formulation will be available as a soft gelatine capsule with a single dose of 50 milligrams, administered orally.
Trial: NCT04686669
Drug: FOR-6219 tablet formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOR-6219 tablet formulation will be available as a tablet with a single dose of 50 milligrams, administered orally.
Trial: NCT00957827
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo BID for five days
Trial: NCT01018680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken by mouth, once daily for 10 weeks
Trial: NCT00003701
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003701
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02196636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, administered orally with approximately 240 mL of buffer
Trial: NCT02196636
Drug: RO6806127
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally with approximately 240 mL of buffer
Trial: NCT00257985
Drug: GTN
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00768456
Drug: Isotonic NaCl
RxNorm normalized name: ISOTON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local Infiltration with NaCl
Trial: NCT03441815
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03281200
Drug: L - Antineoplastic and immunomodulating agents
RxNorm normalized name: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L - Antineoplastic and immunomodulating agents
Trial: NCT03281200
Drug: L01 - Antineoplastic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L01 - Antineoplastic agents
Trial: NCT06369727
Drug: MOB015B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topcal formulation
Trial: NCT06369727
Drug: MOB015B vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topcal formulation
Trial: NCT06369727
Drug: Negative irritant solution of 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative control
Trial: NCT04514653
Drug: Local Steroid
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local steroid
Trial: NCT04514653
Drug: Topical Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid